Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.36 |
| ▸ | MLYCD | O95822 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18501529 | 0.87 | TDP2 (0.41) | TDP2THRBLMNAHTTGABRG2 | |
| SCHEMBL18501523 | 0.81 | TDP2 (0.37) | TDP2THRBLMNAHTTGABRG2 | |
| SCHEMBL18490119 | 0.79 | FFAR4 (0.40) | TDP2THRBLMNAGABRG2GABRB3 | |
| SCHEMBL18490109 | 0.76 | EED (0.40) | TDP2THRBLMNAGABRG2GABRB3 | |
| SCHEMBL18490295 | 0.75 | FFAR1 (0.44) | GABRG2GABRB3GABRA5ALDH1A1MEN1 | |
| SCHEMBL18490104 | 0.74 | FFAR1 (0.38) | TDP2THRBLMNAGABRG2GABRB3 | |
| SCHEMBL18501530 | 0.72 | KAT6A (0.34) | THRBTP53DHODH | |
| SCHEMBL20028542 | 0.72 | KDM4E (0.41) | ALOX5ALDH1A1MEN1KMT2ADHODH | |
| SCHEMBL18490194 | 0.72 | TDP2 (0.39) | TDP2LMNAHTTGABRG2GABRB3 | |
| SCHEMBL18490152 | 0.71 | PRKCZ (0.43) | TDP2HTTGABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920040-B2 | GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-20 | — | — | US | disclosed |
| US-9908873-B2 | GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-06 | — | — | US | disclosed |
| US-9856245-B2 | GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2018-01-02 | — | — | US | disclosed |
| US-20170044148-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-16 | — | — | US | disclosed |
| US-20170044146-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-16 | — | — | US | disclosed |
| US-20170044147-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044148-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR65, GPR52 | TDP2 4772/4885THRB 217/4885LMNA 2740/4885 |
| US-20170044146-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR65, GPR52 | TDP2 4545/4885THRB 201/4885LMNA 3534/4885 |
| US-20170044147-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR55, GPR65 | TDP2 4122/4885THRB 38/4885LMNA 3040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.